Phase 3, multicenter, randomized, double-blind, group sequential, placebo-controlled study to assess efficacy and safety of rimegepant for the treatment of migraine (with or without aura) in children and adolescents 6 to 18 years of age
If you are interested in this clinical trial, please contact Christina Howard on the Children’s Health Research Team.Call 214-456-8559Email
STU-2021-0107
NCT04649242
migraine,rimegepant
Phase 3, multicenter, randomized, double-blind, group sequential, placebo-controlled study to assess efficacy and safety of rimegepant for the treatment of migraine (with or without aura) in children and adolescents 6 to 18 years of age
